BioMedPartners AG, based in Basel, Switzerland, has held the final closing of BioMedInvest III, the company’s third equity venture capital fund, at CHF100 million.
BioMedInvest III is a healthcare venture capital fund which invests in private early-to-mid- stage companies in Switzerland, Germany and neighbouring countries of the European Union.
“We are delighted that the continued success of BioMedInvest convinced many of the major investors of the previous funds to commit also to BioMedInvest III. Among these are the European Investment Fund (EIF) on behalf of the ERP-EIF Dachfonds as cornerstone investor and the Berner Kantonalbank, BEKB. In addition we could gain the Basellandschaftliche Kantonalbank, BLKB, and several important new private persons as new investors,” says Dr Markus Hosang, General Partner at BioMedPartners.
“We are proud of having established BioMedPartners as a leading venture group and early- stage life science investor in Europe over the last fifteen years since its inception. The successful closing of our third equity venture fund is also a major milestone for the future growth of the Life Science Cluster in Switzerland,” adds Thomas Möller, General Partner at BioMedPartners.
The BioMedPartners team includes experienced R&D and venture capital professionals.
With its new fund, BioMedPartners will be able to continue its successful strategy of investing in innovative biopharmaceutical, medical device and diagnostics companies.
“We focus on translating the accelerating progress in science into the development of competitive products that address important patient needs” says Dr Andreas Wallnöfer, General Partner at BioMedPartners. “We select and invest into companies with strong and competent leadership since people are at the core to realise business success and value for patients” adds Stefan Fäs, CFO at BioMedPartners.
With its volume of CHF100 million, BioMedInvest III will invest in 12-15 private companies, supporting them not only by providing funds, but also by taking an active role on the boards of its portfolio companies and by providing senior business expertise and access to its extensive network of industry experts and scientific leaders.
After its first closing in February 2017, the fund has already made its first three investments. These are: Cardior Pharmaceuticals, a German biotech company that develops new therapeutics for the treatment and prevention of heart disease, Amal Therapeutics, a Geneva-based company that pursues novel therapeutic vaccines for the immune-therapy of cancers and Allecra Therapeutics SAS, a late-stage antibiotics company based in the Basel area.
